Lv7
3990 积分 2021-06-28 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1天前
已完结
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
1天前
已完结
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
1天前
求助中
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma
1天前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
1天前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
1天前
已完结
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
1天前
已完结
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
1天前
已完结
Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients
20天前
已完结
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
20天前
已完结
皖公网安备34019202002308
